Skip to main content
Caplight Logo









Toregem BioPharma

Toregem BioPharma

Private
KyotoHealthcare & Life Scienceshttps://toregem.co.jp/

Last Round

Early Funding

May 19, 2026

Total Funding Raised

$22.53M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Toregem BioPharma is a biopharmaceutical company developing regenerative therapeutics for tooth loss.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

tooth regenerationantibody drugbiotechnologytooth regrowthTRG035drug discoverycongenital tooth agenesisUSAG-1 proteinregenerative medicineclinical trialsbiopharmadental innovationtherapeutic antibody

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Toregem BioPharma Comparables

Compare Toregem BioPharma with similar companies based on industry and business-model similarity.

Toregem BioPharma comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
OrganTech Inc.
65%
HysensBio
61%
Air Water Inc.
54%

Toregem BioPharma Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Early FundingMay 19, 2026
Series BAug 30, 2024
Series A ExtensionJul 3, 2023
Series AMar 8, 2022
SeedApr 30, 2021
Seed
May 12, 2020

Toregem BioPharma Investors

Notable investors and investment history

Toregem BioPharma investors
InvestorRounds
Chushin Venture CapitalEarly Funding
Tohoku University Venture PartnersSeries B, Series A Extension
JIC Venture Growth InvestmentsEarly Funding, Series B, Series A Extension
Kyoto Capital PartnersSeries B
MiraidoaSeries A
Astellas Venture ManagementSeries B, Series A Extension, Series A
Mitsubishi UFJ CapitalSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 19, 2026

    $5.3M raised from multiple venture capital firms.

  • Aug 30, 2024

    $10.25M round with participation from Astellas Venture Management and SMBC Venture Capital.

Toregem BioPharma Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Toregem BioPharma Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Toregem BioPharma's valuation, stock price, and market status.

Firmographic Details

HeadquartersKyoto
Employee Range3
Year Founded2020
Last FundingMay 19, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?